Alternative Name: Testosterone undecanoate (TU) + norethisterone enanthate (NET-EN)

Description: An intramuscular injections of 200-mg norethisterone enanthate (NET-EN) combined with 1000-mg testosterone undecanoate (TU), administered every 8 weeks. Mechanism of action is suppression of spermatogenesis.

Product Details

User: Male

Hormonal: Yes

Delivery Method: Injectable

Duration Type: Short-acting

  • injection every 8 weeks

Dose: 200 mg NET-EN, 1000mg TU

Active Pharmaceutical Ingredient (API):
  • testosterone undecanoate
  • norethisterone enanthate

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Bayer HealthCare, CONRAD, WHO

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase II

Active Development: No

Status Details:
  • A global Phase IIb clinical trial was discontinued in April 2011 after a WHO review panel determined that the risks of possible side effects might outweigh the potential benefits to male participants.

Additional Information

  • Kamischke A, et al. (2001) Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86(1): 303-9.

  • Behre HM, et al. (2016) Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men. J Clin Endocrinol Metab.

Vertical Tabs